1. Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19
npj Vaccines. 2025; 10(42). doi: 10.1038/s41541-025-01076-2
2. LmCen-/- based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia
npj Vaccines. 2025: 10(31). doi: 10.1038/s41541-025-01070-8
3. Purification of T7 RNA polymerase for large scale production of mRNA vaccines and therapeutics
Process Biochem. 2024 Dec; 147():391-401. doi:10.1016/j.procbio.2024.10.005
4. Prospective Observational Cohort Study of Tenecteplase: Results From the Indian Registry in Ischemic Stroke-Tenecteplase
J Am Heart Assoc. 2024 Dec 3;13(23):e036382. doi: 10.1161/JAHA.124.036382.
5. Augmenting the landscape of chimeric antigen receptor T-cell therapy
Expert Rev. Anticancer Ther. 2024 Aug; 24(8):755-773. doi:10.1080/14737140.2024.2372330
6. Manufacturing and preclinical toxicity of GLP grade gene deleted attenuated Leishmania donovani parasite vaccine
Sci Rep. 2024; 14:14636. doi:10.1038/s41598-024-64592-6
7. Combinative workflow for mRNA vaccine development
Biochem Biophys Rep. 2024 June 25; 39: 101766. doi: 10.1016/j.bbrep.2024.101766.
8. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Nat Med. 2024 May;30(5):1363-1372. doi: 10.1038/s41591-024-02955-2.
9. Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine
Vaccine. 2024 Mar 7;42(7):1630-1647. doi: 10.1016/j.vaccine.2024.01.087
10. Production of leishmanin skin test antigen from Leishmania donovani for future reintroduction in the field
Nat Commun. 2023 Nov 2; 14(1): 7028. doi: 10.1038/s41467-023-42732-2.
11. Evaluation of self-amplifying mRNA platform for protein expression and genetic stability: Implication for mRNA therapies
Biochem Biophys Res Commun. 2023 Nov 5:680:108-118. doi: 10.1016/j.bbrc.2023.09.016.
12. Systematic clinical and pharmacological monitoring of a PEG-asparaginase biogeneric (HAMSYL) in paediatric patients with newly-diagnosed acute lymphoblastic leukaemia
Pediatr Hematol Oncol. 2023; 8(4:S48. doi: 10.1016/j.phoj.2023.10.122
13. Vaccine for leishmaniasis: New era of CRISPR generated Live attenuated dermotropic Leishmania
J Cell Mol Med. 2022 Mar 21; 1(1):12-16. doi: 10.46439/immunol.1.004.
14. Translational development of a tumor junction opening technology
Nature. 2022 May 11; Scientific Reports; Article number: 7753 (2022).
15. Development of a process for large scale production of PfRH5 in E. coli expression system.
Int J Biol Macromol. 2021 Aug 6;188:169-179. doi: 10.1016/j.ijbiomac.2021.08.014.
16. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.
Commun Biol. 2021 Jul; 4(1):929. doi: 10.1038/s42003-021-02446-x.
17. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia.
Pediatr Blood Cancer. 2021; 3;e29046. doi:10.1002/pbc.29046.
18. Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities.
J Autoimmun. 2021; 118:102614. doi: 10.1016/j.jaut.2021.102614